Simvastatin in Patients With Isolated Arterial Hypertension (STIPPARE)
Recruitment status was Recruiting
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to determine whether combined therapy with simvastatin and hypotensive drugs (ACEI or ARB) may decrease the blood pressure. Moreover, we would like to assess the influence of isolated hypertension on endothelial injury, and on the development of atherosclerosis.
| Condition |
|---|
|
Hypertension |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Simvastatin in the Treatment of Isolated Arterial hyPertension and Prevention of cARdiovascular Events |
plasma
| Estimated Enrollment: | 50 |
| Study Start Date: | November 2009 |
| Estimated Study Completion Date: | January 2012 |
| Estimated Primary Completion Date: | June 2011 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
statin treatment, isolated hypertension
treatment with statins, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
|
|
placebo treatment, isolated hypertension
treatment with placebo, patients with isolated hypertension, with no hyperlipidemia, no diabetes, no smoking
|
Detailed Description:
Hypertension is one of the most important predictors of cardiovascular diseases (CVD). Due to the fact that hypertension frequently coexists with hypercholesterolemia and diabetes which increase the risk of CVDs development, it is advisable to use the optimal combined therapy (hypotensive + hypolipidemic + hypoglycemic)in this group of patients. Statins are the most effective and widely used drugs for the treatment of hypercholesterolemia. According to the available experimental and clinical data they may decrease the blood pressure (BP) in normotensive and hypertensive patients. However, it is still difficult to determine to what degree the reduction of both blood pressure and cardiovascular risk is due to hypotensive or hypolipidemic/pleiotropic effects of statins.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Probability Sample |
Patients hospitalized in the Department of Nephrology, Hypertension and Family Medicine,Clinical Hospital of Medical University of Lodz
Inclusion Criteria:
- isolated hypertension (I or II class according to ESH guidelines 2009)
Exclusion Criteria:
- ischemic heart disease, prior percutaneous coronary intervention (PCI), prior coronary artery bypass grafting (CABG), heart failure, diabetes, hyperlipidemia, active smokers
Contacts and Locations| Contact: Marta Michalska, MSc | 501154853 ext +48 | michalska_marta84@wp.pl |
| Contact: Maciej Banach, MD PhD | 604593040 ext +48 | maciejbanach@aol.co.uk |
| Poland | |
| Departament of Nephrology, Hypertension and Family Medicine, Clinical Hospital of Medical University of Lodz | Recruiting |
| Lodz, Poland, 90-549 | |
| Study Chair: | Maciej Banach, MD PhD | Departament of Hypertension , Medical University of Lodz |
More Information
Publications:
| Responsible Party: | Maciej Banach, Departament of Hypertension |
| ClinicalTrials.gov Identifier: | NCT01017835 History of Changes |
| Other Study ID Numbers: | 503-5139-2 |
| Study First Received: | November 20, 2009 |
| Last Updated: | November 20, 2009 |
| Health Authority: | Poland: Ethics Committee |
Keywords provided by Medical Universtity of Lodz:
|
statins isolated hypertension atherosclerosis lipid profile |
Additional relevant MeSH terms:
|
Hypertension Vascular Diseases Cardiovascular Diseases Simvastatin Hypolipidemic Agents Antimetabolites Molecular Mechanisms of Pharmacological Action |
Pharmacologic Actions Lipid Regulating Agents Therapeutic Uses Hydroxymethylglutaryl-CoA Reductase Inhibitors Anticholesteremic Agents Enzyme Inhibitors |
ClinicalTrials.gov processed this record on May 23, 2013